Partial
Mostly Aligned
Patient Risk:
Low
Summary
Partial alignment. The claims largely reflect label-supported adverse effects and certain mechanism/dosing statements, but there are multiple unsupported or contradicted training-related claims and notable omissions (pregnancy and pediatric safety).
Category Scores
Accurate Statements
Pregabalin acts on the central nervous system to reduce nerve pain signals.
12.1
Effects peak 1-2 hours after dosing.
12.3
Start low-dose (50-75 mg).
2.1
Pregabalin has a black box warning for suicidal thoughts.
5.3
Lyrica commonly causes dizziness.
5.5
Lyrica commonly causes weight gain.
5.8
Unsupported Statements
Lyrica commonly causes dry mouth.
Xerostomia is not listed as a common adverse reaction in the cited sections.
Lyrica commonly causes blurred vision.
Blurred vision not described as a common AE in the cited sections.
Dizziness can impair performance during training.
Label does not discuss impairment in training contexts.
Fatigue can impair performance during training.
Not described in training impairment context.
Muscle weakness can impair performance during training.
Not described in training impairment context.
Coordination problems can impair performance during training.
Not described in training impairment context.
Balance issues during training.
Not described in training impairment context.
Reduced stamina during training.
Not described in training impairment context.
These effects increase fall or injury risk in workouts.
No labeled statement quantifying increased fall risk in workouts.
Pregabalin elevates fall risk by 2-3 times, especially early in treatment.
No numeric fall-risk increase provided in labeling.
Sweating worsens dry mouth during training with pregabalin.
No label data linking sweating to training with pregabalin in these sections.
Elevated heart rate heightens dizziness during training with pregabalin.
Not described in the cited sections.
Dehydration intensifies fatigue during training with pregabalin.
Not described in the cited sections.
Effects last 12-24 hours.
Label does not state this duration for effects.
Most acute effects (dizziness, sleepiness) fade after 1-2 weeks as the body adjusts.
Label does not state this pace of adjustment.
Training tolerance improves over time for many.
Not described in the labeled sections.
20-30% discontinue due to ongoing issues.
Discontinuation rate not stated in the cited labeling.
Time doses away from workouts.
No such dosing-direction in the cited sections.
Stay hydrated.
Hydration guidance not explicitly stated in the cited sections.
Seek medical help for severe dizziness.
Label does not specify thresholds for urgent medical help.
Seek medical help for rapid swelling.
Explicit guidance to seek medical help for rapid swelling not provided.
Seek medical help for mood changes.
Mood changes are addressed, but explicit seeking medical help phrasing varies.
Contradictions
Low
AI Statement
Most acute effects (dizziness, sleepiness) fade after 1-2 weeks as the body adjusts.
Label Reference
5.5
Important Omissions
Pregnancy risk (8.1) and pediatric safety (8.4) sections not addressed in extracted claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Omissions on pregnancy and pediatric safety; several training-impairment extrapolations lack label support; some duration/impairment claims are not consistently supported by labeling.
Suggested Improvement
Limit conclusions to label-supported statements; avoid extrapolations about training performance or non-labeled time courses; ensure pregnancy/pediatric safety sections are addressed in summaries.